Three new classes of targeted agents have been approved for the treatment of CLL in the last decade: BTK inhibitors (ibrutinib, acalabrutinib and zanubrutinib), the BCL2 inhibitor (venetoclax) and PI3K inhibitors (idelalisib and duvelisib). The gene discussed is BTK; the disease is B-cell chronic lymphocytic leukemia.